PD-L1-positive cancers may indicate immune active tumors that could be sensitive to anti-PD-1 and/or PD-L1 therapies because of their correlation with poor prognosis in many of these malignancies, including lung adenocarcinoma50,.51 This evidence concerns the gene CD274 and cancer.